498 related articles for article (PubMed ID: 20594324)
1. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.
Jafri SH; Glass J; Shi R; Zhang S; Prince M; Kleiner-Hancock H
J Exp Clin Cancer Res; 2010 Jul; 29(1):87. PubMed ID: 20594324
[TBL] [Abstract][Full Text] [Related]
2. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
Wang LH; Li Y; Yang SN; Wang FY; Hou Y; Cui W; Chen K; Cao Q; Wang S; Zhang TY; Wang ZZ; Xiao W; Yang JY; Wu CF
Br J Cancer; 2014 Jan; 110(2):341-52. PubMed ID: 24300974
[TBL] [Abstract][Full Text] [Related]
3. Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo.
Attoub S; Sperandio O; Raza H; Arafat K; Al-Salam S; Al Sultan MA; Al Safi M; Takahashi T; Adem A
Fundam Clin Pharmacol; 2013 Oct; 27(5):557-69. PubMed ID: 22788741
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3.
Ku JM; Hong SH; Kim HI; Kim MJ; Kim SK; Kim M; Choi SY; Park J; Kim HK; Kim JH; Seo HS; Shin YC; Ko SG
Phytomedicine; 2020 Jan; 66():153109. PubMed ID: 31790894
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effects of thymoquinone, caffeic acid phenethyl ester and resveratrol on A549 non-small cell lung cancer cells exposed to benzo(a)pyrene.
Ulasli SS; Celik S; Gunay E; Ozdemir M; Hazman O; Ozyurek A; Koyuncu T; Unlu M
Asian Pac J Cancer Prev; 2013; 14(10):6159-64. PubMed ID: 24289642
[TBL] [Abstract][Full Text] [Related]
6. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Yull F; Khabele D
J Ovarian Res; 2015 Jul; 8():46. PubMed ID: 26215403
[TBL] [Abstract][Full Text] [Related]
7. Thymoquinone enhanced the antitumor activity of cisplatin in human bladder cancer 5637 cells in vitro.
Khodadadi F; Khorashadizadeh M; Ghasemi F
Mol Biol Rep; 2023 Jul; 50(7):5767-5775. PubMed ID: 37219672
[TBL] [Abstract][Full Text] [Related]
8. d-Borneol enhances cisplatin sensitivity via p21/p27-mediated S-phase arrest and cell apoptosis in non-small cell lung cancer cells and a murine xenograft model.
Li J; Yuan J; Li Y; Wang J; Gong D; Xie Q; Ma R; Wang J; Ren M; Lu D; Xu Z
Cell Mol Biol Lett; 2022 Jul; 27(1):61. PubMed ID: 35883026
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo inhibitory effect of the combination of Wenxia Changfu formula [see text] with cisplatin in non-small cell lung cancer.
Ji XM; Ouyang B; Liu H; Liu GW; Wu ZC; Yu HY; Wang CY; Wang ZX; Wang WP
Chin J Integr Med; 2011 Dec; 17(12):908-16. PubMed ID: 22139542
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
11. Thymoquinone inhibits proliferation and invasion of human nonsmall-cell lung cancer cells via ERK pathway.
Yang J; Kuang XR; Lv PT; Yan XX
Tumour Biol; 2015 Jan; 36(1):259-69. PubMed ID: 25238880
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin and photodynamic therapy exert synergistic inhibitory effects on small-cell lung cancer cell viability and xenograft tumor growth.
Cheng YS; Peng YB; Yao M; Teng JP; Ni D; Zhu ZJ; Zhuang BF; Yang ZY
Biochem Biophys Res Commun; 2017 Jun; 487(3):567-572. PubMed ID: 28431928
[TBL] [Abstract][Full Text] [Related]
14. Emodin induces apoptosis of lung cancer cells through ER stress and the TRIB3/NF-κB pathway.
Su J; Yan Y; Qu J; Xue X; Liu Z; Cai H
Oncol Rep; 2017 Mar; 37(3):1565-1572. PubMed ID: 28184934
[TBL] [Abstract][Full Text] [Related]
15. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
[TBL] [Abstract][Full Text] [Related]
16. Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo.
Xu D; Ma Y; Zhao B; Li S; Zhang Y; Pan S; Wu Y; Wang J; Wang D; Pan H; Liu L; Jiang H
Oncol Rep; 2014 May; 31(5):2063-70. PubMed ID: 24603952
[TBL] [Abstract][Full Text] [Related]
17. Plumbagin from Plumbago Zeylanica L induces apoptosis in human non-small cell lung cancer cell lines through NF- κB inactivation.
Xu TP; Shen H; Liu LX; Shu YQ
Asian Pac J Cancer Prev; 2013; 14(4):2325-31. PubMed ID: 23725135
[TBL] [Abstract][Full Text] [Related]
18. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
[TBL] [Abstract][Full Text] [Related]
19. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
20. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer.
Lu W; Zuo Y; Feng Y; Zhang M
Tumour Biol; 2014 Nov; 35(11):10699-705. PubMed ID: 25070488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
